

## Policy

### Rapid Assessment of Commissioning Implications for 1862 Vedolizumab for Ulcerative Colitis for pre pubertal children

Key Implications	Proposed Approach	Rationale / Notes
Activity	No: patients affected in current financial year:	Incidence for 3-18 years: around 250 For post pubertal children: $250 \times 60\% = 150$ children (assume 60% children are under the age of 11)
	No: patients affected in a full financial year:	Incidence for 3-18 years: around 250 For post pubertal children: $250 \times 60\% = 150$ children (assume 60% children are under the age of 11)
Finance	Funded via:  Other ( please explain rationale)	Not applicable
Estimated Savings / Investment	Estimated net cost / saving in current financial year (pye) in £k:	£0k
	Estimated net cost / saving in full financial year (fye) in £k:	£0k
	Financial advice and assurance received from: [REDACTED] (17/07/19)	
Impact on Provider Landscape	No change	There is no change as the policy is not for routine commissioning.

Equity	Is it anticipated that the proposal can be delivered equitably across England?	Yes
Inequality	Is the proposal likely to disproportionately advantage or disadvantage any groups with protected characteristics?  No	There is no change as the policy is not for routine commissioning.
Commissioner Actions	<i>Please set out list of key proposed actions to secure delivery (including dates)</i>	To monitor and ensure that this treatment is not commissioned